Abrocitinib

Abrocitinib
Clinical data
Other names	PF-04965842
Routes of; administration	Oral
Identifiers
CAS Number	1622902-68-4;
PubChem CID	78323835;
ChemSpider	68006894 ;
UNII	73SM5SF3OR;
KEGG	D11400 ;
ChEMBL	ChEMBL3655081;
Chemical and physical data
Formula	C14H21N5O2S
Molar mass	323.42 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3;
	InChI InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+ ; Key:IUEWXNHSKRWHDY-PHIMTYICSA-N ;

Abrocitinib (code name PF-04965842) is a Janus kinase inhibitor drug which is currently under investigation for the treatment of atopic dermatitis. It was developed by Pfizer.

Mechanism of action

It is a selective inhibitor of the enzyme janus kinase 1 (JAK1).[1]

Timeline

April 2016: initiation of Phase 2b trial
December 2017: initiation of JADE Mono-1 Phase 3 trial[2]
May 2018: Results of Phase 2b trial posted

References

"Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial". JAMA Dermatology. October 2, 2019. doi:10.1001/jamadermatol.2019.2855. Retrieved November 27, 2019.
"Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)". ClinicalTrials.gov. Retrieved November 26, 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial". JAMA Dermatology. October 2, 2019. doi:10.1001/jamadermatol.2019.2855. Retrieved November 27, 2019.

[2] "Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)". ClinicalTrials.gov. Retrieved November 26, 2019.